Albumin–Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology
For patients with HCC, ABC is a useful predictive biomarker because it can be calculated in a simple manner and because it provides accurate prognostic information.
Authors
- Akihiko Oshita (ORCID: https://orcid.org/0000-0001-8417-7599)
- Naruhiko Honmyo (ORCID: https://orcid.org/0000-0002-6201-6812)
- Hideki Ohdan (ORCID: https://orcid.org/0000-0002-9066-1288)
- Takeshi Tadokoro (ORCID: https://orcid.org/0000-0001-6617-9750)
- Masakazu Hashimoto (ORCID: https://orcid.org/0000-0002-9617-4843)
- Koichi Oishi (ORCID: https://orcid.org/0000-0003-1159-3908)
- Tsuyoshi Kobayashi (ORCID: https://orcid.org/0000-0001-7364-1798)
- Takashi Onoe (ORCID: https://orcid.org/0000-0002-8188-4623)
- Shintaro Kuroda (ORCID: https://orcid.org/0000-0001-9881-0420)
- Tomoyuki Abe
- Toshihiko Kohashi
- Masahiro Ohira
Institutions
- Hiroshima University (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Hiroshima Prefectural Hospital (JP)
- Hiroshima University Hospital (JP)
- Higashihiroshima Medical Center (JP)
- North Medical Center (JP)
- Chugoku Rosai Hospital (JP)
- National Hospital Organization (JP)
- Kure Medical Center (JP)
- Onomichi General Hospital (JP)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1245/s10434-024-16650-6
- Citations
- 6
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 2.80
Funders
- Hiroshima University